Genovis AB (GENOb)

Stockholm
Currency in SEK
26.000
+0.050(+0.19%)
Closed·
GENOb Scorecard
Full Analysis
Impressive gross profit margins
GENOb is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.15026.000
52 wk Range
17.10031.250
Key Statistics
Edit
Prev. Close
25.95
Open
25.95
Day's Range
25.15-26
52 wk Range
17.1-31.25
Volume
36.36K
Average Volume (3m)
123.02K
1-Year Change
-15.86%
Book Value / Share
3.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GENOb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
38.333
Upside
+47.44%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Genovis AB News & Analysis

No news in this category
Looks like there are no results in this news category

Genovis AB Company Profile

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Compare GENOb to Peers and Sector

Metrics to compare
GENOb
Peers
Sector
Relationship
P/E Ratio
72.0x−2.6x−0.4x
PEG Ratio
−3.140.080.00
Price/Book
7.3x1.8x2.6x
Price / LTM Sales
13.7x3.3x3.1x
Upside (Analyst Target)
30.8%65.0%51.1%
Fair Value Upside
Unlock35.6%8.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 38.333
(+47.44% Upside)

Earnings

Latest Release
May 21, 2025
EPS / Forecast
0.05 / 0.10
Revenue / Forecast
32.30M / 31.40M
EPS Revisions
Last 90 days

FAQ

What Is the Genovis AB (GENOb) Stock Price Today?

The Genovis AB stock price today is 26.00

What Stock Exchange Does Genovis AB Trade On?

Genovis AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Genovis AB?

The stock symbol for Genovis AB is "GENOb."

What Is the Genovis AB Market Cap?

As of today, Genovis AB market cap is 1.70B.

What Is Genovis AB's Earnings Per Share (TTM)?

The Genovis AB EPS (TTM) is 0.36.

When Is the Next Genovis AB Earnings Date?

Genovis AB will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is GENOb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Genovis AB Stock Split?

Genovis AB has split 10 times.

How Many Employees Does Genovis AB Have?

Genovis AB has 33 employees.

What is the current trading status of Genovis AB (GENOb)?

As of 14 Jun 2025, Genovis AB (GENOb) is trading at a price of 26.00, with a previous close of 25.95. The stock has fluctuated within a day range of 25.15 to 26.00, while its 52-week range spans from 17.10 to 31.25.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.